文献速递复苏、休克与脓毒症心脑血管急症

评估心脏骤停检测技术临床有效性的前瞻性研究设计预测

Design projections for prospective studies evaluating the clinical effectiveness of cardiac arrest detection technologies.
PubMed 文献 · Resuscitation · 2025-06-13
一句话结论基于不列颠哥伦比亚心脏骤停登记数据的设计分析显示,院外心脏骤停检测技术的前瞻性试验需要极大招募目标,且估计治疗效果最高的亚组并非发病率最高的亚组。

该研究分析2019-2020年不列颠哥伦比亚心脏骤停登记中可能受益于心脏骤停检测的EMS治疗与未治疗病例,按年龄(0-35、36-55、56-65、65+)和性别分层,估计各层识别与治疗效应,并计算不同主要临床结局所需的样本量。风险人群中哨兵病例11382例,各层发病率从每10万人18.3例到395例不等。生存结局统计效率最高的亚组为56-65岁男性(需171676例),EMS治疗或初始可除颤心律结局效率最高的亚组为65岁以上男性(分别需7608例和66962例)。结论认为前瞻性试验需大招募目标,高治疗效应亚组与高发病率亚组不一致,大型普通人群试验需多中心和创新招募策略。

要点

  • 风险人群9739356人中,11382例哨兵病例符合纳入标准,各年龄-性别层发病率从每10万人18.3例到395例不等。
  • 以生存至出院为主要结局时,统计效率最高的亚组为56-65岁男性,总需171676例。
  • 以EMS治疗为主要结局时,65岁以上男性为最有效亚组,总需7608例。
  • 以初始可除颤心律为主要结局时,65岁以上男性为最有效亚组,总需66962例。
  • 估计治疗效果最高的亚组并非发病率最高的亚组,普通人群大型试验需多中心与创新招募策略。

适用人群与场景

  • 不列颠哥伦比亚心脏骤停登记(2019-2020年)中EMS治疗和EMS未治疗、可能受益于心脏骤停检测的病例。
  • 按年龄(0-35、36-55、56-65、65+)和性别分层分析。

研究设计与关键结果

  • 研究类型为基于登记数据的设计分析,分析2019-2020年不列颠哥伦比亚心脏骤停登记中EMS治疗与未治疗、可能受益于心脏骤停检测的病例。
  • 风险人群9739356人,11382例哨兵病例符合纳入标准,各年龄-性别层发病率从每10万人18.3例到395例不等。
  • 以生存至出院为主要结局时,统计效率最高的亚组为56-65岁男性,总需171676例。
  • 以EMS治疗为主要结局时,65岁以上男性为最有效亚组,总需7608例。
  • 以初始可除颤心律为主要结局时,65岁以上男性为最有效亚组,总需66962例。

证据类型、等级与局限

  • 证据类型:基于登记数据的设计分析(研究论文)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为前瞻性心脏骤停检测技术试验将需要大招募目标,高估计治疗效应亚组与高发病率亚组不一致,大型普通人群试验需多中心和创新招募策略,可能受益于产业合作。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent developments have illustrated the feasibility of scalable out-of hospital cardiac arrest (OHCA) detection using consumer-wearable products. While initial evidence is promising, the real-world effectiveness of these technologies is unproven and design decisions to minimize false positives may constrain clinical impact. To support the real-world evaluation of these technologies, we analyzed registry data and evaluated strategies for a clinical trial.

METHODS: We analyzed Emergency Medical Services (EMS)-treated and EMS-untreated cases in the British Columbia Cardiac Arrest Registry (2019-2020) who may have benefitted from cardiac arrest detection. Within strata formed by Age (0-35, 36-55, 56-65, 65+) and Sex, we estimated strata-specific treatment effects from recognition and calculated the required sample sizes for a set of potential primary clinical outcomes for a trial (survival to hospital discharge, initial shockable cardiac rhythm, EMS treatment). We compared this with population incidence to inform prospective recruitment requirements.

RESULTS: Within a population-at-risk of 9,739,356, 11,382 sentinel cases met criteria for inclusion. Strata-specific incidence ranged from 18.3 per 100,000 to 395 per 100,000. The most statistically efficient subgroup for a survival outcome was Males aged 56-65 (171,676 needed, total). For a trial outcome of EMS treatment or initial shockable rhythm, Males over 65 were the most efficient subgroup within which to test the intervention (7,608 and 66,962 needed, total respectively).

CONCLUSION: A prospective trial of OHCA detection technologies will require large recruitment targets. Subgroups with the highest estimated treatment effect are not those with the highest incidence. Large trials in the general population will require multiple centers and innovative recruitment strategies that may be aided by partnership with industry.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Hutton J, Khalili M, Lingawi S, et al. Design projections for prospective studies evaluating the clinical effectiveness of cardiac arrest detection technologies. Resuscitation. 2025. PMID: 40517937. doi:10.1016/j.resuscitation.2025.110681

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。